Plain-English translation of NCT07523737 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether three medications taken together—, selinexor, and an anti-PD-1 antibody called tislelizumab—can help people whose brain lymphoma has returned or no longer responds to standard treatment. Brain lymphomas are aggressive cancers that form in the brain and are very difficult to treat. Right now, doctors have few good options for patients who've already tried the standard first-line chemotherapy, so researchers are hoping this combination of the medication might give patients a better chance at recovery.
When brain lymphoma comes back or stops responding to standard chemotherapy, patients have very limited treatment choices, and outcomes are usually poor—with survival often measured in just months. This trial exists to see if this combination of the treatment can improve survival and quality of life for these patients, especially those who otherwise would have few options left.
You likely qualify if…
You likely don't qualify if…
You will receive the three medications as an induction treatment lasting 6 cycles (about 18 weeks), with taken by mouth on certain days, selinexor taken by mouth on specific days, and the anti-PD-1 antibody given as an intravenous infusion. During and after this initial treatment phase, you'll have regular blood tests and imaging scans to see how well the medication is working. If your cancer responds well, you may choose to stop and receive additional consolidation therapy like stem cell transplant or radiation; if not, you can continue on a lower-dose maintenance treatment until your disease progresses or the side effects become unacceptable.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China